1. Introduction {#s0005}
===============

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are effective treatment modalities for non-gynecologic peritoneal surface malignancies. Peritoneal carcinomatosis is present in 10--30% of patients with gastrointestinal cancer at the time of initial surgery and usually is associated with a poor prognosis ([@b0040]). The goal of HIPEC is to target remaining microscopic residual tumor following an optimal complete resection. In the last decade, randomized clinical trials have demonstrated significant improved overall survival in patients with gastric cancer who underwent CRS followed by HIPEC compared to cytoreduction or systemic therapy alone ([@b0075], [@b0060]). Although utilizing HIPEC for the treatment of colorectal cancer remains controversial, the highest median overall survival to date was seen in a recent multicenter clinical trial of metastatic colorectal cancer patients after treatment with CRS and HIPEC of 41.7 months ([@b0050]). CRS and HIPEC have also shown clinical benefit for patients with peritoneal carcinomatosis originating from the appendix ([@b0030]) and malignant peritoneal mesothelioma ([@b0070]). It remains as the only potential cure for patients with pseudomyxoma peritonei ([@b0015]). CRS improved both overall survival and progression free survival in colon cancers metastatic to the ovaries. Although statistical significance was not reached in breast or gastric cancer with ovarian metastasis, a trend towards improved benefit was noted ([@b0005]).

Both intraoperative and postoperative disease burden predicts overall survival. The Peritoneal Cancer Index (PCI) quantifies disease burden according to amount and location using intraoperative direct visualization. Higher PCI values are associated with decreased survival following CRS and HIPEC ([@b0020]). To evaluate the extent of surgical debulking, Glehen and Gilly created the CC score that defines residual tumor diameter: no visible residual tumor (CC-0), less than 2.5 mm (CC-1), 2.5 mm to 2.5 cm (CC-2), and greater than 2.5 cm (CC-3). Their studies indicated that the benefits of HIPEC diminished as the CC score increased, and CC score was the most significant independent prognostic factor for patient survival ([@b0035]). As expected, patients undergoing incomplete cytoreduction faced increased morbidity with poorer survival ([@b0045]).

Our institution takes a unique approach to patients with non-gynecologic peritoneal carcinomatosis. Female patients deemed optimal candidates for CRS and HIPEC undergo pre-operative counseling with both surgical oncology and gynecologic oncology. Using a shared decision-making model with the patient, hysterectomy and bilateral salpingo-oophorectomy are recommended as part of the cytoreductive effort regardless of whether gynecologic organ involvement is suspected preoperatively. To date, no literature has examined the role for concurrent hysterectomy and bilateral salpingo-oophorectomy in these non-gynecologic peritoneal carcinomatosis patients undergoing HIPEC. In this case series, we describe the demographics, pre-operative, intraoperative, and final pathology findings, the operative times, and immediate postoperative outcomes at our institution.

2. Methods {#s0010}
==========

A retrospective chart review was performed on twenty consecutive patients presenting to the Markey Cancer Center between August 1, 2018, and February 28, 2020, who underwent cytoreductive surgery with concurrent hysterectomy and bilateral salpingo-oophorectomy and HIPEC for a non-gynecologic malignancy at the University of Kentucky. This review was conducted in accordance with the US Common Rule and approved by the Institutional Review Board (IRB). Demographic variables, such as age, race, BMI, preoperative assessment, intraoperative findings, final pathologic diagnosis, and 30-day surgical outcomes were included in the analysis.

Our institution utilizes an open approach to CRS through a midline laparotomy incision. Initial exploration quantifies PCI. All female patients, regardless of gross disease, undergo the following procedures: resection of the greater and lesser omentum, appendectomy, cholecystectomy, hysterectomy, bilateral salpingo-oophorectomy, and tumor debulking with the goal of achieving complete resection of all visible disease. A closed system technique is used for administration of HIPEC with the Genesis Medical System. The abdomen is warmed with hyperthermic saline to 43 °C and chemotherapy is infused and perfused for 30--90 min with simultaneous agitation of the abdomen. We typically administer cisplatin for 60 min for gastric cancer and mitomycin C for 90 min in appendiceal and colorectal primaries. Following administration, the abdomen is rinsed with three liters of saline, the abdomen re-opened and irrigated, and the definitive visceral reconstruction performed ([@b0055]).

3. Results {#s0015}
==========

The cohort was comprised of twenty female patients aged 18--75 years old (mean 52 years). Reflective of Kentucky demographics, race was predominantly Caucasian (15/20, 75%). The most common cancer type was mucinous appendiceal adenocarcinoma (9/20, 45%). Several of the mucinous appendiceal subtypes were considered low-grade appendiceal neoplasms (4/9, 44.4%). BMI ranged from 17.3--49.2 kg/m^2^ (mean 30.24 kg/m^2^). Demographic characteristics of all subjects are shown in [Table 1](#t0005){ref-type="table"}.Table 1Demographic Characteristics.CharacteristicsNo. Patients (%)**Total**20 (1 0 0)Age GroupRange (18--75 years) \<52 years8 (40.0) 52+ years12 (60.0)Race Caucasian15 (75.0) African American2 (10.0) Other3 (15.0)Cancer Type Mucinous Appendiceal9 (45.0) Colonic Adenocarcinoma3 (15.0) Gastric Adenocarcinoma3 (15.0) Urachal Mucinous1 (5.0) Mesothelioma2 (10.0) Small Bowel Adenocarcinoma2 (10.0)Pathologic Grade 15 (25.0) 26 (30.0) 33 (15.0) Unknown6 (30.0)BMI (kg/m^2)^ 15--256 (30.0) 26--357 (35.0) 36--456 (5.61) 46--551 (5.0)

Nine patients (9/20, 45%) had evidence of gynecologic organ disease on pre-operative assessment, either from imaging studies with positron emission tomography (PET) or computed tomography (CT) scan or from pre-operative assessment via diagnostic laparoscopy to determine eligibility for HIPEC. Thirteen patients (13/20, 65%) had gross involvement of the gynecologic organs at the time of surgery, and sixteen (16/20, 80%) had confirmation of disease on final pathology. Of the eleven patients with negative pre-operative assessment, five had gross visible disease at the time of surgery with positive final pathologic analysis. An additional three had microscopic disease on final pathology that was not visible preoperatively or intraoperatively as shown in [Fig. 1](#f0005){ref-type="fig"}.Fig. 1Pelvic organ involvement by non-gynecologic malignancies flowsheet.

The average PCI of the cases was 7.9 with seven patients having a PCI ≥ 10. At the completion of surgery, eighteen patients (90%) had a CC-0 score, and two patients (10%) had a score of CC-1 at the time of HIPEC. Mean estimated blood loss was 152.5 mL (range 50--500 mL) for the non-gynecologic portion and 106.5 mL (range 25--400 mL) for the gynecologic portion of the cases. These findings are displayed in [Table 2](#t0010){ref-type="table"}. The mean operative time of the cases was 481 min (range 271--790 min). Patients were discharged home after a mean of 7 days (range 4--16 days).Table 2Surgical Demographics.CharacteristicsNo. Patients (%)**Total**20 (1 0 0)PCI values Range (mean)0--22 (7.9)Cytoreduction Score CC-018 (90) CC-12 (10)Operative Time Range (mean), minutes318--790 (481.45)Estimated blood loss, average in cc (range) Gynecologic106.5 (25--400 mL) Non-gynecologic152.5 (50--500 mL)Length of hospital stay Range (mean), days4--16 (7.4)

Complications are summarized using the Clavien-Dindo Classification system in [Table 3](#t0015){ref-type="table"} ([@b0025]). One intraoperative cystotomy occurred during the completion of the hysterectomy as part of the oncologic resection for her disease burden and is not included in the graded complications. This patient had recurrent pseudomyxoma peritonei that had fistulized into the uterus. No other intraoperative complications were noted.Table 3Morbidity after surgical cytoreduction and HIPEC.MorbidityGradeTotal (%)I-IIIIIIV**Gastrointestinal tract**3 (15.0)Paralytic ileus2----Anastomotic leak------Strangulated hernia--1--**Hematologic**5 (25.0)Blood transfusion2----Wound hematoma--1--Leukopenia requiring intervention2----**Infections**3 (15.0)Superficial wound infection1----Deep surgical site11--**Pulmonary**4 (20.0)Pleural effusions11--Pneumothorax--1--Aspiration pneumonia----1**Renal**2 (10.0)Acute Kidney Injury2----**Hospital Readmissions** Readmission \< 30 days4 (20.0) Readmission \> 30--90 days0 (0.0)

In the peri- and post-operative course, nine patients (45%) recovered uneventfully. Most of the complications recorded were grade I-II. Five patients had grade III complications, and one had a grade IV complication. One patient who had extensive diaphragmatic resection required a chest tube on postoperative day two for a pneumothorax occurrence. One patient developed pancytopenia felt to be secondary to sequestered chemotherapy perfusate fluid in the pleural cavity that resolved after interventional radiology guided thoracentesis and growth factor support. One patient was noted to have a small pleural effusion postoperatively that was expectantly managed and later developed a right upper quadrant hematoma requiring aspiration but never required a transfusion. The two other grade III complications are described further with their readmissions. The grade IV complication occurred in a patient who developed pneumonia following an aspiration event on postoperative day four requiring ICU care and intubation, resulting in a sixteen-day postoperative hospital stay.

In the subsequent six-week period following discharge from the initial hospitalization, four patients required readmission. One patient was readmitted with dehydration from high colostomy output. Another patient was readmitted three weeks postoperatively with a peri-splenic abscess that resolved with drain placement. A third patient was found to have a strangulated hernia three weeks postoperatively and underwent an exploratory laparotomy with mesh repair. The final patient was readmitted three weeks postoperatively for a paralytic ileus treated expectantly and a pelvic fluid collection managed with antibiotics.

4. Discussion {#s0020}
=============

This descriptive case series examines the potential to maximize cytoreductive surgery efforts for non-gynecologic cancers undergoing HIPEC by including a gynecologic oncologist for a planned hysterectomy and bilateral salpingo-oophorectomy, regardless of preoperative imaging or intraoperative findings at the time of surgery. Overall, eighty percent of patients in our series had metastasis to gynecologic organs. Even in patients with a negative preoperative assessment for gynecologic involvement, 72.7% (8 of 11 patients) were confirmed to have either gross disease intraoperatively or microscopic disease on final pathology. This suggests that by not including a planned hysterectomy or bilateral salpingo-oophorectomy at the time of surgery, a less optimal debulking may occur. In addition, by involving the gynecologic oncology service in preoperative assessment, patients were counseled about the risks and benefits of a total hysterectomy and bilateral salpingo-oophorectomy before the procedure and were mentally prepared to undergo that portion of the surgery.

In non-gynecologic cancers, HIPEC and CRS have an estimated morbidity of 30--50%, mortality of 1--5%, with a mean operative time of 388--550 min depending on the extent of peritoneal procedures ([@b0010]). A positive correlation between duration of surgery, number of peritonectomy procedures and resections, and number of suture lines correlated with combined grade III-IV morbidities. Duration of surgery was the most common predictor of morbidity and was associated with pancreatitis, cardiovascular toxicity, wound sepsis, systemic sepsis, bile leak, and deep vein thrombosis. In a study by Stephens, et al., their average patient had 2.1 prior surgeries and a PCI of 19 with the majority (150/183) having appendiceal primary as the source ([@b0065]).

In our patients, mean operative time including the hysterectomy and bilateral salpingo-oophorectomy was 481 min, which is similar to that quoted in prior studies. Our perioperative and postoperative complications are also similar to what is quoted in the literature, suggesting that the addition of a planned hysterectomy and bilateral salpingo-oophorectomy with each case may not add to the overall morbidity of the procedure. The inclusion of a hysterectomy added an average of 106 mL of blood loss to the case. The only event directly linked to hysterectomy in our series was a cystotomy created during en bloc resection of the uterus with tumor that was not unexpected given her disease extent and required oncologic resection. A second patient requiring readmission three weeks postoperatively for ileus was found to have a pelvic fluid collection requiring antibiotics that could have been secondary to the hysterectomy portion of the case. Our patients had an average PCI of 7.9 with seven of twenty patients having a PCI ≥ 10. The PCI of the patients in the prior studies mentioned was 19, suggesting a higher surgical complexity, although this does not take into consideration the surgical and medical history of our patients prior to the operation.

The key limitation to this study is its retrospective nature and case series design. Based on our practice approach, a control group that did not have concurrent hysterectomy and bilateral salpingo-oophorectomy is unavailable for comparison of outcomes. However, this is the first study to take a deeper look into concurrent hysterectomy and bilateral salpingo-oophorectomy in non-gynecologic cancer cases. Eighty percent of patients in our series had gynecologic organ involvement including both expected and unexpected final pathologic findings. Prior studies would suggest that maximal cytoreduction leads to improved outcomes, but further prospective trials would be needed to fully understand the survival impact of hysterectomy and bilateral salpingo-oophorectomy in this setting.

5. Conclusion {#s0025}
=============

CRS and HIPEC are treatment options for patients with non-gynecologic cancers, and survival outcomes have been correlated with the extent of CRS. Our experience at Markey Cancer Center suggests a benefit to concurrent hysterectomy and bilateral salpingo-oophorectomy as part of the cytoreductive effort in these cases. Twenty-five percent (5/20) of patients had gross involvement of gynecologic organs at the time of surgery that was unanticipated based on preoperative evaluation. An additional fifteen percent (3/20) of our patients had microscopic involvement that was unexpected given both pre- and intraoperative assessment. Involving a gynecologic oncologist in the care of these patients preoperatively allows for additional counseling and patient preparation. Our morbidity and operative times are within the reported range of prior literature, even with our inclusion of a hysterectomy and bilateral salpingo-oophorectomy at the time of CRS. We feel there is benefit in a multidisciplinary approach to these patients and that concurrent hysterectomy and bilateral salpingo-oophorectomy at the time of CRS and HIPEC may maximize the CRS without adding significant surgical morbidity.
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